{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:28:48Z","timestamp":1790886528082,"version":"4.1.0"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T00:00:00Z","timestamp":1725667200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005357","name":"Slovak Research and Development Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005357","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic &amp; Medicinal Chemistry"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.bmc.2024.117909","type":"journal-article","created":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T03:09:15Z","timestamp":1726110555000},"page":"117909","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Design of inhibitors of SARS-CoV-2 papain-like protease deriving from GRL0617: Structure\u2013activity relationships"],"prefix":"10.1016","volume":"113","author":[{"given":"Lukas","family":"Kerti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9378-5860","authenticated-orcid":false,"given":"Vladimir","family":"Frecer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2024.117909_b0005","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202200327","article-title":"SARS-CoV-2 papain-like protease: structure, function and inhibition","volume":"23","author":"Ullrich","year":"2022","journal-title":"Chembiochem"},{"key":"10.1016\/j.bmc.2024.117909_b0010","doi-asserted-by":"crossref","DOI":"10.3201\/eid2908.221580","article-title":"Omicron COVID-19 case estimates based on previous SARS-CoV-2 wastewater load, regional municipality of peel, Ontario, Canada","volume":"29","author":"Cheng","year":"2023","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.bmc.2024.117909_b0015","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1038\/s41467-023-37254-w","article-title":"Potent and selective covalent inhibition of the papain-like protease from SARS-CoV-2","volume":"14","author":"Sanders","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2024.117909_b0020","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3390\/v16010102","article-title":"Timely monitoring of SARS-CoV-2 RNA fragments in wastewater shows the emergence of JN.1 (BA.2.86.1.1, Clade 23I) in Berlin, Germany","volume":"16","author":"Bartel","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.bmc.2024.117909_b0025","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12929-022-00847-6","article-title":"Beyond the vaccines: a glance at the small molecule and peptide-based anti-COVID19 arsenal","volume":"29","author":"Nepali","year":"2022","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.bmc.2024.117909_b0030","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/cmdc.202000223","article-title":"Drug development and medicinal chemistry efforts toward SARS-coronavirus and covid-19 therapeutics","volume":"15","author":"Ghosh","year":"2020","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmc.2024.117909_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2023.129489","article-title":"SARS-CoV-2 papain-like protease (PLpro) inhibitory and antiviral activity of small molecule derivatives for drug leads","volume":"96","author":"Ghosh","year":"2023","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2024.117909_b0040","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2020106275","article-title":"Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2","volume":"39","author":"Klemm","year":"2020","journal-title":"EMBO J"},{"key":"10.1016\/j.bmc.2024.117909_b0045","unstructured":"Paxlovid | European Medicines Agency. <https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/paxlovid>."},{"key":"10.1016\/j.bmc.2024.117909_b0050","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.89801","article-title":"A retrospective cohort study of Paxlovid efficacy depending on treatment time in hospitalized COVID-19 patients","volume":"13","author":"Du","year":"2024","journal-title":"Elife"},{"key":"10.1016\/j.bmc.2024.117909_b0055","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-020-2601-5","article-title":"Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity","volume":"587","author":"Shin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2024.117909_b0060","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/s41590-021-01035-8","article-title":"Altered ISGylation drives aberrant macrophage-dependent immune responses during SARS-CoV-2 infection","volume":"22","author":"Munnur","year":"2021","journal-title":"Nat Immunol"},{"key":"10.1016\/j.bmc.2024.117909_b0065","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1042\/BST20220839","article-title":"ISG15 driven cellular responses to virus infection","volume":"50","author":"Munnur","year":"2022","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.bmc.2024.117909_b0070","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abd4596","article-title":"Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: a framework for anti\u2013COVID-19 drug design","volume":"6","author":"Rut","year":"2020","journal-title":"Sci Adv"},{"key":"10.1016\/j.bmc.2024.117909_b0075","doi-asserted-by":"crossref","first-page":"7561","DOI":"10.1021\/acs.jmedchem.2c00303","article-title":"Progress and challenges in targeting the SARS-CoV-2 papain-like protease","volume":"65","author":"Tan","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117909_b0080","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.antiviral.2017.11.001","article-title":"Nsp3 of coronaviruses: Structures and functions of a large multi-domain protein","volume":"149","author":"Lei","year":"2018","journal-title":"Antivir Res"},{"key":"10.1016\/j.bmc.2024.117909_b0085","doi-asserted-by":"crossref","first-page":"27553","DOI":"10.1021\/acsomega.3c03215","article-title":"Preferability of molnupiravir, an anti-COVID-19 drug, toward purine nucleosides: a quantum mechanical study","volume":"8","author":"Ibrahim","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.bmc.2024.117909_b0090","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1126\/science.1085952","article-title":"Characterization of a novel coronavirus associated with severe acute respiratory syndrome","volume":"300","author":"Rota","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.bmc.2024.117909_b0095","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/s41586-022-04532-4","article-title":"Bat coronaviruses related to SARS-CoV-2 and infectious for human cells","volume":"604","author":"Temmam","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2024.117909_b0100","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2024.117909_b0105","unstructured":"van Boheemen S. Virus discovery and characterization using next-generation sequencing. Thesis. Erasmus University Rotterdam, NL; 2014."},{"key":"10.1016\/j.bmc.2024.117909_b0110","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00473-12","article-title":"Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans","volume":"3","author":"van Boheemen","year":"2012","journal-title":"mBio"},{"key":"10.1016\/j.bmc.2024.117909_b0115","doi-asserted-by":"crossref","first-page":"15189","DOI":"10.1128\/JVI.79.24.15189-15198.2005","article-title":"The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity","volume":"79","author":"Barretto","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.bmc.2024.117909_b0120","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41467-021-21060-3","article-title":"Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors","volume":"12","author":"Osipiuk","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2024.117909_b0125","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1021\/jm401712t","article-title":"X-ray structural and biological evaluation of a series of potent and highly selective inhibitors of human coronavirus papain-like proteases","volume":"57","author":"B\u00e1ez-Santos","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117909_b0130","doi-asserted-by":"crossref","first-page":"16119","DOI":"10.1073\/pnas.0805240105","article-title":"A noncovalent class of papain-like protease\/deubiquitinase inhibitors blocks SARS virus replication","volume":"105","author":"Ratia","year":"2008","journal-title":"PNAS"},{"key":"10.1016\/j.bmc.2024.117909_b0135","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1021\/acscentsci.1c00519","article-title":"Discovery of SARS-CoV-2 papain-like protease inhibitors through a combination of high-throughput screening and a FlipGFP-based reporter assay","volume":"7","author":"Ma","year":"2021","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.bmc.2024.117909_b0140","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.3390\/pathogens11091008","article-title":"Association between mutations in papain-like protease (PLpro) of SARS-CoV-2 with COVID-19 clinical outcomes","volume":"11","author":"Tan","year":"2022","journal-title":"Pathogens"},{"key":"10.1016\/j.bmc.2024.117909_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109754","article-title":"A molecular sensor determines the ubiquitin substrate specificity of SARS-CoV-2 papain-like protease","volume":"36","author":"Patchett","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.bmc.2024.117909_b0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1010667","article-title":"Amino acid variants of SARS-CoV-2 papain-like protease have impact on drug binding","volume":"18","author":"Perlinska","year":"2022","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.bmc.2024.117909_b0155","doi-asserted-by":"crossref","DOI":"10.1111\/sji.13044","article-title":"Interactions between SARS coronavirus 2 papain-like protease and immune system: a potential drug target for the treatment of COVID-19","volume":"94","author":"Mahmoudvand","year":"2021","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.bmc.2024.117909_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107772","article-title":"Modulation of extracellular ISG15 signaling by pathogens and viral effector proteins","volume":"31","author":"Swaim","year":"2020","journal-title":"Cell Rep"},{"key":"10.1016\/j.bmc.2024.117909_b0165","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41564-021-00884-1","article-title":"ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-CoV-2 papain-like protease to evade host innate immunity","volume":"6","author":"Liu","year":"2021","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.bmc.2024.117909_b0170","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/s41579-018-0020-5","article-title":"ISG15 in antiviral immunity and beyond","volume":"16","author":"Perng","year":"2018","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.bmc.2024.117909_b0175","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.3390\/ijms22031308","article-title":"The SARS-coronavirus infection cycle: a survey of viral membrane proteins, their functional interactions and pathogenesis","volume":"22","author":"Wong","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmc.2024.117909_b0180","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/ni0102-20","article-title":"Regulatory functions of ubiquitination in the immune system","volume":"3","author":"Ben-Neriah","year":"2002","journal-title":"Nat Immunol"},{"key":"10.1016\/j.bmc.2024.117909_b0185","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.virol.2015.02.033","article-title":"Ubiquitination in the antiviral immune response","volume":"479\u2013480","author":"Davis","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.bmc.2024.117909_b0190","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1074\/jbc.M114.593871","article-title":"Interferon-stimulated Gene 15 (ISG15) and ISG15-linked proteins can associate with members of the selective autophagic process, histone deacetylase 6 (HDAC6) and SQSTM1\/p62*","volume":"290","author":"Nakashima","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2024.117909_b0195","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41467-020-20718-8","article-title":"The complex structure of GRL0617 and SARS-CoV-2 PLpro reveals a hot spot for antiviral drug discovery","volume":"12","author":"Fu","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2024.117909_b0200","doi-asserted-by":"crossref","first-page":"27356","DOI":"10.1074\/jbc.M502814200","article-title":"Crystal structure of the interferon-induced ubiquitin-like protein ISG15*","volume":"280","author":"Narasimhan","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2024.117909_b0205","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.molcel.2016.04.016","article-title":"Recognition of Lys48-linked di-ubiquitin and deubiquitinating activities of the SARS coronavirus papain-like protease","volume":"62","author":"B\u00e9k\u00e9s","year":"2016","journal-title":"Mol Cell"},{"key":"10.1016\/j.bmc.2024.117909_b0210","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1128\/JVI.79.7.4550-4551.2005","article-title":"Deubiquitination, a new function of the severe acute respiratory syndrome coronavirus papain-like protease?","volume":"79","author":"Sulea","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.bmc.2024.117909_b0215","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.virol.2013.11.040","article-title":"MERS-CoV papain-like protease has deISGylating and deubiquitinating activities","volume":"450\u2013451","author":"Mielech","year":"2014","journal-title":"Virology"},{"key":"10.1016\/j.bmc.2024.117909_b0220","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/s41590-021-01056-3","article-title":"ISG15 secretion exacerbates inflammation in SARS-CoV-2 infection","volume":"22","author":"Cao","year":"2021","journal-title":"Nat Immunol"},{"key":"10.1016\/j.bmc.2024.117909_b0225","doi-asserted-by":"crossref","first-page":"12910","DOI":"10.1074\/jbc.REV120.013930","article-title":"The molecular virology of coronaviruses","volume":"295","author":"Hartenian","year":"2020","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2024.117909_b0230","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1021\/acsinfecdis.0c00168","article-title":"Characterization and noncovalent inhibition of the deubiquitinase and deISGylase activity of SARS-CoV-2 papain-like protease","volume":"6","author":"Freitas","year":"2020","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.bmc.2024.117909_b0235","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2022.876212","article-title":"Inhibitors of SARS-CoV-2 PLpro","volume":"10","author":"Calleja","year":"2022","journal-title":"Front Chem"},{"key":"10.1016\/j.bmc.2024.117909_b0240","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1016\/j.bmc.2017.06.052","article-title":"Therapeutic peptides: Historical perspectives, current development trends, and future directions","volume":"26","author":"Lau","year":"2018","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2024.117909_b0245","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.bmc.2024.117909_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113863","article-title":"Identification of a dual acting SARS-CoV-2 proteases inhibitor through in silico design and step-by-step biological characterization","volume":"226","author":"Di Sarno","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2024.117909_b0255","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd5524","article-title":"Drug repurposing: misconceptions, challenges, and opportunities for academic researchers","volume":"13","author":"Begley","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bmc.2024.117909_b0260","doi-asserted-by":"crossref","first-page":"5228","DOI":"10.1021\/jm900611t","article-title":"Structure-based design, synthesis, and biological evaluation of a series of novel and reversible inhibitors for the severe acute respiratory syndrome\u2212coronavirus papain-like protease","volume":"52","author":"Ghosh","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117909_b0265","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1038\/s41467-023-38031-5","article-title":"Dual domain recognition determines SARS-CoV-2 PLpro selectivity for human ISG15 and K48-linked di-ubiquitin","volume":"14","author":"Wydorski","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2024.117909_b0270","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.apsb.2020.08.014","article-title":"Crystal structure of SARS-CoV-2 papain-like protease","volume":"11","author":"Gao","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.bmc.2024.117909_b0275","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1021\/acs.jmedchem.1c01307","article-title":"Design of SARS-CoV-2 PLpro inhibitors for COVID-19 antiviral therapy leveraging binding cooperativity","volume":"65","author":"Shen","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117909_b0280","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1021\/jm1004489","article-title":"Severe acute respiratory syndrome coronavirus papain-like novel protease inhibitors: design, synthesis, protein\u2212ligand X-ray structure and biological evaluation","volume":"53","author":"Ghosh","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117909_b0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114572","article-title":"Chalcone-amide, a privileged backbone for the design and development of selective SARS-CoV\/SARS-CoV-2 papain-like protease inhibitors","volume":"240","author":"Valipour","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2024.117909_b0290","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1021\/cb500917m","article-title":"Inhibitor recognition specificity of MERS-CoV papain-like protease may differ from that of SARS-CoV","volume":"10","author":"Lee","year":"2015","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.bmc.2024.117909_b0295","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/cmdc.202000548","article-title":"Structure-activity relationships of benzamides and isoindolines designed as SARS-CoV protease inhibitors effective against SARS-CoV-2","volume":"16","author":"Welker","year":"2021","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmc.2024.117909_b0300","unstructured":"Pegan S, et al. Compositions and methods of treatment for sars-Cov-2 through papain protease inhibition. WO2022\/072975; 2022."},{"key":"10.1016\/j.bmc.2024.117909_b0305","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1021\/acschemneuro.7b00185","article-title":"Drug-target kinetics in drug discovery","volume":"9","author":"Tonge","year":"2018","journal-title":"ACS Chem Nerosci"},{"key":"10.1016\/j.bmc.2024.117909_b0310","doi-asserted-by":"crossref","first-page":"4683","DOI":"10.1021\/acs.biochem.5b00284","article-title":"Rational modulation of the induced-fit conformational change for slow-onset inhibition in mycobacterium tuberculosis InhA","volume":"54","author":"Lai","year":"2015","journal-title":"Biochemistry"},{"key":"10.1016\/j.bmc.2024.117909_b0315","unstructured":"Sharma R, Agarwal S. Novel amide derivatives. WO2022\/070048; 2022."},{"key":"10.1016\/j.bmc.2024.117909_b0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116011","article-title":"Structure-based design of SARS-CoV-2 papain-like protease inhibitors","volume":"264","author":"Jadhav","year":"2024","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2024.117909_b0325","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1126\/science.adm9724","article-title":"Design of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model","volume":"383","author":"Tan","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.bmc.2024.117909_b0330","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s11030-021-10198-3","article-title":"Exploring naphthyl derivatives as SARS-CoV papain-like protease (PLpro) inhibitors and its implications in COVID-19 drug discovery","volume":"26","author":"Amin","year":"2022","journal-title":"Mol Div"},{"key":"10.1016\/j.bmc.2024.117909_b0335","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ejmech.2018.10.018","article-title":"Naphthalene, a versatile platform in medicinal chemistry: Sky-high perspective","volume":"161","author":"Makar","year":"2019","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2024.117909_b0340","doi-asserted-by":"crossref","first-page":"8633","DOI":"10.3390\/ijms24108633","article-title":"Structure-based design of potent peptidomimetic inhibitors covalently targeting SARS-CoV-2 papain-like protease","volume":"24","author":"Wang","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmc.2024.117909_b0345","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1021\/acs.jmedchem.1c02022","article-title":"Design and evaluation of a novel peptide-drug conjugate covalently targeting SARS-CoV-2 papain-like protease","volume":"65","author":"Liu","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117909_b0350","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1087057116671509","article-title":"A perspective on the kinetics of covalent and irreversible inhibition","volume":"22","author":"Strelow","year":"2017","journal-title":"SLAS Disc"},{"key":"10.1016\/j.bmc.2024.117909_b0355","unstructured":"He W, et al. CN 114957110, antiviral compound as well as preparation method and application thereof. <https:\/\/patentscope.wipo.int\/search\/en\/detail.jsf?docId=CN373569627&_cid=P22-LSS0S9-57419-1>."},{"key":"10.1016\/j.bmc.2024.117909_b0360","unstructured":"He W, et al. CN 114957165 antiviral compound as well as preparation method and application thereof. <https:\/\/patentscope.wipo.int\/search\/en\/detail.jsf?docId=CN373569641&_cid=P22-LSS0TO-57650-1>."},{"key":"10.1016\/j.bmc.2024.117909_b0365","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202300216","article-title":"A patent review on SARS coronavirus papain-like protease (PLpro) inhibitors","volume":"18","author":"Brian Chia","year":"2023","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmc.2024.117909_b0370","unstructured":"Dickson J, et al. Compounds and methods for treating coronaviruses. WO2023\/064493; 2023."},{"key":"10.1016\/j.bmc.2024.117909_b0375","unstructured":"Wang J, et al. Compositions and methods for inhibiting PLPRO protease activity and for preventing and treating SARS-COV-2 infection. WO2022\/192665; 2022."},{"key":"10.1016\/j.bmc.2024.117909_b0380","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.antiviral.2014.12.015","article-title":"The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds","volume":"115","author":"B\u00e1ez-Santos","year":"2015","journal-title":"Antivir Res"},{"key":"10.1016\/j.bmc.2024.117909_b0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.chembiol.2021.04.020","article-title":"Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2","volume":"28","author":"Shan","year":"2021","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.bmc.2024.117909_b0390","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2022.861209","article-title":"Insights into drug repurposing, as well as specificity and compound properties of piperidine-based SARS-CoV-2 PLpro inhibitors","volume":"10","author":"Calleja","year":"2022","journal-title":"Front Chem"},{"key":"10.1016\/j.bmc.2024.117909_b0395","article-title":"Discovery and characterization of novel potent non-covalent small molecule inhibitors targeting papain-like protease from SARS-CoV-2","author":"Zheng","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.bmc.2024.117909_b0400","first-page":"17","article-title":"High-throughput screening of SARS-CoV-2 main and papain-like protease inhibitors","volume":"14","author":"Zang","year":"2023","journal-title":"Prot Cell"},{"key":"10.1016\/j.bmc.2024.117909_b0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.128099","article-title":"Promising anti-SARS-CoV-2 drugs by effective dual targeting against the viral and host proteases","volume":"43","author":"Elseginy","year":"2021","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2024.117909_b0410","doi-asserted-by":"crossref","unstructured":"Forrestall, K., et al. Dual inhibition of coronavirus Mpro and PLpro enzymes by phenothiazines and their antiviral activity; 2023. <https:\/\/doi.org\/10.1101\/2023.09.11.557219> [2023.09.11.557219 Preprint at].","DOI":"10.1101\/2023.09.11.557219"},{"key":"10.1016\/j.bmc.2024.117909_b0415","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1021\/jm5019093","article-title":"PAINS in the assay: chemical mechanisms of assay interference and promiscuous enzymatic inhibition observed during a sulfhydryl-scavenging HTS","volume":"58","author":"Dahlin","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117909_b0420","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1089\/adt.2015.674","article-title":"How to triage PAINS-Full research","volume":"14","author":"Dahlin","year":"2016","journal-title":"ASSAY Drug Dev Technol"},{"key":"10.1016\/j.bmc.2024.117909_b0425","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1021\/acschembio.7b00903","article-title":"Seven year itch: pan-assay interference compounds (PAINS) in 2017 - utility and limitations","volume":"13","author":"Baell","year":"2018","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.bmc.2024.117909_b0430","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1089\/adt.2009.0247","article-title":"Profiling the NIH small molecule repository for compounds that generate H2O2 by redox cycling in reducing environments","volume":"8","author":"Soares","year":"2010","journal-title":"ASSAY Drug Dev Technol"},{"key":"10.1016\/j.bmc.2024.117909_b0435","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.cbpa.2010.10.022","article-title":"Redox cycling compounds generate H2O2 in HTS buffers containing strong reducing reagents-real hits or promiscuous artifacts?","volume":"15","author":"Johnston","year":"2011","journal-title":"Curr Opin Chem Biol"}],"container-title":["Bioorganic &amp; Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089624003237?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089624003237?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T12:31:10Z","timestamp":1728477070000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089624003237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":87,"alternative-id":["S0968089624003237"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2024.117909","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design of inhibitors of SARS-CoV-2 papain-like protease deriving from GRL0617: Structure\u2013activity relationships","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2024.117909","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"117909"}}